nodes	percent_of_prediction	percent_of_DWPC	metapath
Topiramate—GRIK5—prostate gland—urinary bladder cancer	0.0188	0.0883	CbGeAlD
Topiramate—GRIK3—prostate gland—urinary bladder cancer	0.0188	0.0883	CbGeAlD
Topiramate—GRIK4—renal system—urinary bladder cancer	0.0176	0.0825	CbGeAlD
Topiramate—GRIK3—seminal vesicle—urinary bladder cancer	0.0159	0.0747	CbGeAlD
Topiramate—GRIK3—female reproductive system—urinary bladder cancer	0.0103	0.0482	CbGeAlD
Topiramate—GRIK3—vagina—urinary bladder cancer	0.0093	0.0436	CbGeAlD
Topiramate—CYP2C19—urine—urinary bladder cancer	0.0093	0.0436	CbGeAlD
Topiramate—GRIK1—vagina—urinary bladder cancer	0.00884	0.0414	CbGeAlD
Topiramate—CA5A—female reproductive system—urinary bladder cancer	0.00753	0.0353	CbGeAlD
Topiramate—CA7—renal system—urinary bladder cancer	0.00625	0.0293	CbGeAlD
Topiramate—GRIK5—lymph node—urinary bladder cancer	0.00602	0.0282	CbGeAlD
Topiramate—GRIK3—lymph node—urinary bladder cancer	0.00602	0.0282	CbGeAlD
Topiramate—CYP3A4—urine—urinary bladder cancer	0.0055	0.0258	CbGeAlD
Topiramate—CA5B—prostate gland—urinary bladder cancer	0.00535	0.0251	CbGeAlD
Topiramate—CA9—female reproductive system—urinary bladder cancer	0.0044	0.0206	CbGeAlD
Topiramate—CA12—renal system—urinary bladder cancer	0.00406	0.019	CbGeAlD
Topiramate—CA4—prostate gland—urinary bladder cancer	0.00369	0.0173	CbGeAlD
Topiramate—CA5B—urethra—urinary bladder cancer	0.00358	0.0168	CbGeAlD
Topiramate—CA12—female reproductive system—urinary bladder cancer	0.00325	0.0152	CbGeAlD
Topiramate—CA1—renal system—urinary bladder cancer	0.00322	0.0151	CbGeAlD
Topiramate—CA4—seminal vesicle—urinary bladder cancer	0.00312	0.0146	CbGeAlD
Topiramate—CA2—prostate gland—urinary bladder cancer	0.00306	0.0143	CbGeAlD
Topiramate—CA5B—female reproductive system—urinary bladder cancer	0.00292	0.0137	CbGeAlD
Topiramate—CA5B—vagina—urinary bladder cancer	0.00264	0.0124	CbGeAlD
Topiramate—CA2—seminal vesicle—urinary bladder cancer	0.00259	0.0121	CbGeAlD
Topiramate—CA1—female reproductive system—urinary bladder cancer	0.00258	0.0121	CbGeAlD
Topiramate—SCN5A—vagina—urinary bladder cancer	0.00256	0.012	CbGeAlD
Topiramate—CA4—renal system—urinary bladder cancer	0.00251	0.0118	CbGeAlD
Topiramate—CA4—urethra—urinary bladder cancer	0.00247	0.0116	CbGeAlD
Topiramate—CA2—epithelium—urinary bladder cancer	0.00225	0.0105	CbGeAlD
Topiramate—CA2—smooth muscle tissue—urinary bladder cancer	0.00217	0.0102	CbGeAlD
Topiramate—CA2—renal system—urinary bladder cancer	0.00209	0.00977	CbGeAlD
Topiramate—CA4—female reproductive system—urinary bladder cancer	0.00201	0.00944	CbGeAlD
Topiramate—CA5B—lymph node—urinary bladder cancer	0.00171	0.008	CbGeAlD
Topiramate—CA2—female reproductive system—urinary bladder cancer	0.00167	0.00783	CbGeAlD
Topiramate—CYP2C19—vagina—urinary bladder cancer	0.00165	0.00772	CbGeAlD
Topiramate—CA2—vagina—urinary bladder cancer	0.00151	0.00708	CbGeAlD
Topiramate—CA1—lymph node—urinary bladder cancer	0.00151	0.00706	CbGeAlD
Topiramate—CYP3A4—renal system—urinary bladder cancer	0.00135	0.0063	CbGeAlD
Topiramate—CA4—lymph node—urinary bladder cancer	0.00118	0.00552	CbGeAlD
Topiramate—CYP3A4—female reproductive system—urinary bladder cancer	0.00108	0.00505	CbGeAlD
Topiramate—CA2—lymph node—urinary bladder cancer	0.000977	0.00458	CbGeAlD
Topiramate—Epistaxis—Doxorubicin—urinary bladder cancer	0.00024	0.000353	CcSEcCtD
Topiramate—Angiopathy—Methotrexate—urinary bladder cancer	0.000239	0.000352	CcSEcCtD
Topiramate—Sinusitis—Doxorubicin—urinary bladder cancer	0.000239	0.000351	CcSEcCtD
Topiramate—Immune system disorder—Methotrexate—urinary bladder cancer	0.000238	0.00035	CcSEcCtD
Topiramate—Dizziness—Fluorouracil—urinary bladder cancer	0.000238	0.00035	CcSEcCtD
Topiramate—Visual impairment—Epirubicin—urinary bladder cancer	0.000238	0.00035	CcSEcCtD
Topiramate—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000238	0.00035	CcSEcCtD
Topiramate—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000237	0.000349	CcSEcCtD
Topiramate—Chills—Methotrexate—urinary bladder cancer	0.000237	0.000348	CcSEcCtD
Topiramate—Diarrhoea—Cisplatin—urinary bladder cancer	0.000234	0.000344	CcSEcCtD
Topiramate—Erythema multiforme—Epirubicin—urinary bladder cancer	0.000233	0.000343	CcSEcCtD
Topiramate—Alopecia—Methotrexate—urinary bladder cancer	0.000233	0.000343	CcSEcCtD
Topiramate—Vomiting—Gemcitabine—urinary bladder cancer	0.000233	0.000343	CcSEcCtD
Topiramate—Bradycardia—Doxorubicin—urinary bladder cancer	0.000232	0.000342	CcSEcCtD
Topiramate—Mental disorder—Methotrexate—urinary bladder cancer	0.000231	0.00034	CcSEcCtD
Topiramate—Rash—Gemcitabine—urinary bladder cancer	0.000231	0.00034	CcSEcCtD
Topiramate—Dermatitis—Gemcitabine—urinary bladder cancer	0.000231	0.000339	CcSEcCtD
Topiramate—Eye disorder—Epirubicin—urinary bladder cancer	0.000231	0.000339	CcSEcCtD
Topiramate—Hypersensitivity—Etoposide—urinary bladder cancer	0.00023	0.000339	CcSEcCtD
Topiramate—Tinnitus—Epirubicin—urinary bladder cancer	0.00023	0.000338	CcSEcCtD
Topiramate—Malnutrition—Methotrexate—urinary bladder cancer	0.00023	0.000338	CcSEcCtD
Topiramate—Erythema—Methotrexate—urinary bladder cancer	0.00023	0.000338	CcSEcCtD
Topiramate—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000229	0.000338	CcSEcCtD
Topiramate—Headache—Gemcitabine—urinary bladder cancer	0.000229	0.000338	CcSEcCtD
Topiramate—Flushing—Epirubicin—urinary bladder cancer	0.000229	0.000337	CcSEcCtD
Topiramate—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000229	0.000337	CcSEcCtD
Topiramate—Vomiting—Fluorouracil—urinary bladder cancer	0.000229	0.000337	CcSEcCtD
Topiramate—Rhinitis—Doxorubicin—urinary bladder cancer	0.000229	0.000337	CcSEcCtD
Topiramate—Hepatitis—Doxorubicin—urinary bladder cancer	0.000228	0.000336	CcSEcCtD
Topiramate—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000228	0.000336	CcSEcCtD
Topiramate—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000227	0.000334	CcSEcCtD
Topiramate—Rash—Fluorouracil—urinary bladder cancer	0.000227	0.000334	CcSEcCtD
Topiramate—Dermatitis—Fluorouracil—urinary bladder cancer	0.000227	0.000334	CcSEcCtD
Topiramate—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000227	0.000333	CcSEcCtD
Topiramate—Headache—Fluorouracil—urinary bladder cancer	0.000226	0.000332	CcSEcCtD
Topiramate—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000225	0.000332	CcSEcCtD
Topiramate—Oedema peripheral—Doxorubicin—urinary bladder cancer	0.000225	0.000331	CcSEcCtD
Topiramate—Dysgeusia—Methotrexate—urinary bladder cancer	0.000225	0.000331	CcSEcCtD
Topiramate—Asthenia—Etoposide—urinary bladder cancer	0.000224	0.00033	CcSEcCtD
Topiramate—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000224	0.00033	CcSEcCtD
Topiramate—Angiopathy—Epirubicin—urinary bladder cancer	0.000224	0.000329	CcSEcCtD
Topiramate—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000224	0.000329	CcSEcCtD
Topiramate—Immune system disorder—Epirubicin—urinary bladder cancer	0.000223	0.000328	CcSEcCtD
Topiramate—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000222	0.000327	CcSEcCtD
Topiramate—Back pain—Methotrexate—urinary bladder cancer	0.000222	0.000327	CcSEcCtD
Topiramate—Chills—Epirubicin—urinary bladder cancer	0.000221	0.000326	CcSEcCtD
Topiramate—Pruritus—Etoposide—urinary bladder cancer	0.000221	0.000326	CcSEcCtD
Topiramate—Visual impairment—Doxorubicin—urinary bladder cancer	0.00022	0.000324	CcSEcCtD
Topiramate—Alopecia—Epirubicin—urinary bladder cancer	0.000218	0.000321	CcSEcCtD
Topiramate—Nausea—Gemcitabine—urinary bladder cancer	0.000218	0.00032	CcSEcCtD
Topiramate—Vomiting—Cisplatin—urinary bladder cancer	0.000217	0.000319	CcSEcCtD
Topiramate—Vision blurred—Methotrexate—urinary bladder cancer	0.000216	0.000318	CcSEcCtD
Topiramate—Mental disorder—Epirubicin—urinary bladder cancer	0.000216	0.000318	CcSEcCtD
Topiramate—Erythema multiforme—Doxorubicin—urinary bladder cancer	0.000216	0.000318	CcSEcCtD
Topiramate—Rash—Cisplatin—urinary bladder cancer	0.000215	0.000317	CcSEcCtD
Topiramate—Dermatitis—Cisplatin—urinary bladder cancer	0.000215	0.000316	CcSEcCtD
Topiramate—Erythema—Epirubicin—urinary bladder cancer	0.000215	0.000316	CcSEcCtD
Topiramate—Malnutrition—Epirubicin—urinary bladder cancer	0.000215	0.000316	CcSEcCtD
Topiramate—Diarrhoea—Etoposide—urinary bladder cancer	0.000214	0.000315	CcSEcCtD
Topiramate—Nausea—Fluorouracil—urinary bladder cancer	0.000214	0.000315	CcSEcCtD
Topiramate—Eye disorder—Doxorubicin—urinary bladder cancer	0.000213	0.000314	CcSEcCtD
Topiramate—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000213	0.000313	CcSEcCtD
Topiramate—Tinnitus—Doxorubicin—urinary bladder cancer	0.000213	0.000313	CcSEcCtD
Topiramate—Anaemia—Methotrexate—urinary bladder cancer	0.000212	0.000312	CcSEcCtD
Topiramate—Cardiac disorder—Doxorubicin—urinary bladder cancer	0.000212	0.000312	CcSEcCtD
Topiramate—Flushing—Doxorubicin—urinary bladder cancer	0.000212	0.000312	CcSEcCtD
Topiramate—Flatulence—Epirubicin—urinary bladder cancer	0.000212	0.000311	CcSEcCtD
Topiramate—Tension—Epirubicin—urinary bladder cancer	0.000211	0.00031	CcSEcCtD
Topiramate—Dysgeusia—Epirubicin—urinary bladder cancer	0.00021	0.000309	CcSEcCtD
Topiramate—Nervousness—Epirubicin—urinary bladder cancer	0.000209	0.000307	CcSEcCtD
Topiramate—Back pain—Epirubicin—urinary bladder cancer	0.000208	0.000306	CcSEcCtD
Topiramate—Angiopathy—Doxorubicin—urinary bladder cancer	0.000207	0.000305	CcSEcCtD
Topiramate—Malaise—Methotrexate—urinary bladder cancer	0.000207	0.000305	CcSEcCtD
Topiramate—Dizziness—Etoposide—urinary bladder cancer	0.000207	0.000304	CcSEcCtD
Topiramate—Muscle spasms—Epirubicin—urinary bladder cancer	0.000207	0.000304	CcSEcCtD
Topiramate—Immune system disorder—Doxorubicin—urinary bladder cancer	0.000206	0.000303	CcSEcCtD
Topiramate—Vertigo—Methotrexate—urinary bladder cancer	0.000206	0.000303	CcSEcCtD
Topiramate—Mediastinal disorder—Doxorubicin—urinary bladder cancer	0.000206	0.000303	CcSEcCtD
Topiramate—Leukopenia—Methotrexate—urinary bladder cancer	0.000205	0.000302	CcSEcCtD
Topiramate—Chills—Doxorubicin—urinary bladder cancer	0.000205	0.000301	CcSEcCtD
Topiramate—Nausea—Cisplatin—urinary bladder cancer	0.000203	0.000298	CcSEcCtD
Topiramate—Vision blurred—Epirubicin—urinary bladder cancer	0.000202	0.000298	CcSEcCtD
Topiramate—Alopecia—Doxorubicin—urinary bladder cancer	0.000202	0.000297	CcSEcCtD
Topiramate—Cough—Methotrexate—urinary bladder cancer	0.0002	0.000295	CcSEcCtD
Topiramate—Mental disorder—Doxorubicin—urinary bladder cancer	0.0002	0.000294	CcSEcCtD
Topiramate—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000199	0.000293	CcSEcCtD
Topiramate—Convulsion—Methotrexate—urinary bladder cancer	0.000199	0.000293	CcSEcCtD
Topiramate—Vomiting—Etoposide—urinary bladder cancer	0.000199	0.000293	CcSEcCtD
Topiramate—Erythema—Doxorubicin—urinary bladder cancer	0.000199	0.000292	CcSEcCtD
Topiramate—Malnutrition—Doxorubicin—urinary bladder cancer	0.000199	0.000292	CcSEcCtD
Topiramate—Anaemia—Epirubicin—urinary bladder cancer	0.000199	0.000292	CcSEcCtD
Topiramate—Agitation—Epirubicin—urinary bladder cancer	0.000197	0.00029	CcSEcCtD
Topiramate—Rash—Etoposide—urinary bladder cancer	0.000197	0.00029	CcSEcCtD
Topiramate—Dermatitis—Etoposide—urinary bladder cancer	0.000197	0.00029	CcSEcCtD
Topiramate—Headache—Etoposide—urinary bladder cancer	0.000196	0.000288	CcSEcCtD
Topiramate—Flatulence—Doxorubicin—urinary bladder cancer	0.000196	0.000288	CcSEcCtD
Topiramate—Arthralgia—Methotrexate—urinary bladder cancer	0.000195	0.000287	CcSEcCtD
Topiramate—Myalgia—Methotrexate—urinary bladder cancer	0.000195	0.000287	CcSEcCtD
Topiramate—Chest pain—Methotrexate—urinary bladder cancer	0.000195	0.000287	CcSEcCtD
Topiramate—Tension—Doxorubicin—urinary bladder cancer	0.000195	0.000287	CcSEcCtD
Topiramate—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000195	0.000286	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	0.000194	0.000285	CcSEcCtD
Topiramate—Malaise—Epirubicin—urinary bladder cancer	0.000194	0.000285	CcSEcCtD
Topiramate—Discomfort—Methotrexate—urinary bladder cancer	0.000193	0.000284	CcSEcCtD
Topiramate—Nervousness—Doxorubicin—urinary bladder cancer	0.000193	0.000284	CcSEcCtD
Topiramate—Vertigo—Epirubicin—urinary bladder cancer	0.000193	0.000284	CcSEcCtD
Topiramate—Syncope—Epirubicin—urinary bladder cancer	0.000193	0.000283	CcSEcCtD
Topiramate—Leukopenia—Epirubicin—urinary bladder cancer	0.000192	0.000283	CcSEcCtD
Topiramate—Back pain—Doxorubicin—urinary bladder cancer	0.000192	0.000283	CcSEcCtD
Topiramate—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000191	0.000281	CcSEcCtD
Topiramate—Palpitations—Epirubicin—urinary bladder cancer	0.00019	0.000279	CcSEcCtD
Topiramate—Confusional state—Methotrexate—urinary bladder cancer	0.000189	0.000278	CcSEcCtD
Topiramate—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000189	0.000278	CcSEcCtD
Topiramate—Cough—Epirubicin—urinary bladder cancer	0.000187	0.000276	CcSEcCtD
Topiramate—Vision blurred—Doxorubicin—urinary bladder cancer	0.000187	0.000276	CcSEcCtD
Topiramate—Convulsion—Epirubicin—urinary bladder cancer	0.000186	0.000274	CcSEcCtD
Topiramate—Infection—Methotrexate—urinary bladder cancer	0.000186	0.000274	CcSEcCtD
Topiramate—Nausea—Etoposide—urinary bladder cancer	0.000186	0.000273	CcSEcCtD
Topiramate—Hypertension—Epirubicin—urinary bladder cancer	0.000185	0.000273	CcSEcCtD
Topiramate—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.000184	0.000271	CcSEcCtD
Topiramate—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000184	0.00027	CcSEcCtD
Topiramate—Anaemia—Doxorubicin—urinary bladder cancer	0.000184	0.00027	CcSEcCtD
Topiramate—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000183	0.00027	CcSEcCtD
Topiramate—Chest pain—Epirubicin—urinary bladder cancer	0.000183	0.000269	CcSEcCtD
Topiramate—Arthralgia—Epirubicin—urinary bladder cancer	0.000183	0.000269	CcSEcCtD
Topiramate—Myalgia—Epirubicin—urinary bladder cancer	0.000183	0.000269	CcSEcCtD
Topiramate—Agitation—Doxorubicin—urinary bladder cancer	0.000183	0.000269	CcSEcCtD
Topiramate—Anxiety—Epirubicin—urinary bladder cancer	0.000182	0.000268	CcSEcCtD
Topiramate—Skin disorder—Methotrexate—urinary bladder cancer	0.000182	0.000268	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	0.000182	0.000267	CcSEcCtD
Topiramate—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000181	0.000266	CcSEcCtD
Topiramate—Discomfort—Epirubicin—urinary bladder cancer	0.000181	0.000266	CcSEcCtD
Topiramate—Malaise—Doxorubicin—urinary bladder cancer	0.000179	0.000264	CcSEcCtD
Topiramate—Dry mouth—Epirubicin—urinary bladder cancer	0.000179	0.000263	CcSEcCtD
Topiramate—Vertigo—Doxorubicin—urinary bladder cancer	0.000179	0.000263	CcSEcCtD
Topiramate—Anorexia—Methotrexate—urinary bladder cancer	0.000179	0.000263	CcSEcCtD
Topiramate—Syncope—Doxorubicin—urinary bladder cancer	0.000178	0.000262	CcSEcCtD
Topiramate—Leukopenia—Doxorubicin—urinary bladder cancer	0.000178	0.000262	CcSEcCtD
Topiramate—Confusional state—Epirubicin—urinary bladder cancer	0.000177	0.00026	CcSEcCtD
Topiramate—Palpitations—Doxorubicin—urinary bladder cancer	0.000176	0.000258	CcSEcCtD
Topiramate—Oedema—Epirubicin—urinary bladder cancer	0.000175	0.000258	CcSEcCtD
Topiramate—Hypotension—Methotrexate—urinary bladder cancer	0.000175	0.000258	CcSEcCtD
Topiramate—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000175	0.000257	CcSEcCtD
Topiramate—Infection—Epirubicin—urinary bladder cancer	0.000174	0.000256	CcSEcCtD
Topiramate—Cough—Doxorubicin—urinary bladder cancer	0.000173	0.000255	CcSEcCtD
Topiramate—Shock—Epirubicin—urinary bladder cancer	0.000172	0.000254	CcSEcCtD
Topiramate—Convulsion—Doxorubicin—urinary bladder cancer	0.000172	0.000253	CcSEcCtD
Topiramate—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000172	0.000253	CcSEcCtD
Topiramate—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.000172	0.000253	CcSEcCtD
Topiramate—Hypertension—Doxorubicin—urinary bladder cancer	0.000172	0.000252	CcSEcCtD
Topiramate—Tachycardia—Epirubicin—urinary bladder cancer	0.000171	0.000252	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000171	0.000251	CcSEcCtD
Topiramate—Skin disorder—Epirubicin—urinary bladder cancer	0.00017	0.000251	CcSEcCtD
Topiramate—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000169	0.000249	CcSEcCtD
Topiramate—Insomnia—Methotrexate—urinary bladder cancer	0.000169	0.000249	CcSEcCtD
Topiramate—Myalgia—Doxorubicin—urinary bladder cancer	0.000169	0.000249	CcSEcCtD
Topiramate—Chest pain—Doxorubicin—urinary bladder cancer	0.000169	0.000249	CcSEcCtD
Topiramate—Arthralgia—Doxorubicin—urinary bladder cancer	0.000169	0.000249	CcSEcCtD
Topiramate—Anxiety—Doxorubicin—urinary bladder cancer	0.000169	0.000248	CcSEcCtD
Topiramate—Paraesthesia—Methotrexate—urinary bladder cancer	0.000168	0.000247	CcSEcCtD
Topiramate—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	0.000168	0.000247	CcSEcCtD
Topiramate—Discomfort—Doxorubicin—urinary bladder cancer	0.000167	0.000246	CcSEcCtD
Topiramate—Anorexia—Epirubicin—urinary bladder cancer	0.000167	0.000246	CcSEcCtD
Topiramate—Dyspnoea—Methotrexate—urinary bladder cancer	0.000167	0.000246	CcSEcCtD
Topiramate—Somnolence—Methotrexate—urinary bladder cancer	0.000167	0.000245	CcSEcCtD
Topiramate—Dry mouth—Doxorubicin—urinary bladder cancer	0.000166	0.000243	CcSEcCtD
Topiramate—Dyspepsia—Methotrexate—urinary bladder cancer	0.000165	0.000243	CcSEcCtD
Topiramate—Hypotension—Epirubicin—urinary bladder cancer	0.000164	0.000241	CcSEcCtD
Topiramate—Confusional state—Doxorubicin—urinary bladder cancer	0.000164	0.000241	CcSEcCtD
Topiramate—Decreased appetite—Methotrexate—urinary bladder cancer	0.000163	0.00024	CcSEcCtD
Topiramate—Oedema—Doxorubicin—urinary bladder cancer	0.000162	0.000239	CcSEcCtD
Topiramate—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	0.000162	0.000238	CcSEcCtD
Topiramate—Fatigue—Methotrexate—urinary bladder cancer	0.000162	0.000238	CcSEcCtD
Topiramate—Infection—Doxorubicin—urinary bladder cancer	0.000161	0.000237	CcSEcCtD
Topiramate—Pain—Methotrexate—urinary bladder cancer	0.00016	0.000236	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.00016	0.000235	CcSEcCtD
Topiramate—Shock—Doxorubicin—urinary bladder cancer	0.00016	0.000235	CcSEcCtD
Topiramate—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000159	0.000234	CcSEcCtD
Topiramate—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000159	0.000234	CcSEcCtD
Topiramate—Insomnia—Epirubicin—urinary bladder cancer	0.000159	0.000233	CcSEcCtD
Topiramate—Tachycardia—Doxorubicin—urinary bladder cancer	0.000158	0.000233	CcSEcCtD
Topiramate—Skin disorder—Doxorubicin—urinary bladder cancer	0.000158	0.000232	CcSEcCtD
Topiramate—Paraesthesia—Epirubicin—urinary bladder cancer	0.000157	0.000232	CcSEcCtD
Topiramate—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000157	0.000231	CcSEcCtD
Topiramate—Dyspnoea—Epirubicin—urinary bladder cancer	0.000156	0.00023	CcSEcCtD
Topiramate—Somnolence—Epirubicin—urinary bladder cancer	0.000156	0.000229	CcSEcCtD
Topiramate—Anorexia—Doxorubicin—urinary bladder cancer	0.000155	0.000227	CcSEcCtD
Topiramate—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000154	0.000227	CcSEcCtD
Topiramate—Dyspepsia—Epirubicin—urinary bladder cancer	0.000154	0.000227	CcSEcCtD
Topiramate—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000153	0.000225	CcSEcCtD
Topiramate—Decreased appetite—Epirubicin—urinary bladder cancer	0.000152	0.000224	CcSEcCtD
Topiramate—Hypotension—Doxorubicin—urinary bladder cancer	0.000152	0.000223	CcSEcCtD
Topiramate—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	0.000151	0.000223	CcSEcCtD
Topiramate—Fatigue—Epirubicin—urinary bladder cancer	0.000151	0.000222	CcSEcCtD
Topiramate—Pain—Epirubicin—urinary bladder cancer	0.00015	0.000221	CcSEcCtD
Topiramate—Constipation—Epirubicin—urinary bladder cancer	0.00015	0.000221	CcSEcCtD
Topiramate—Urticaria—Methotrexate—urinary bladder cancer	0.000149	0.000219	CcSEcCtD
Topiramate—Abdominal pain—Methotrexate—urinary bladder cancer	0.000148	0.000218	CcSEcCtD
Topiramate—Body temperature increased—Methotrexate—urinary bladder cancer	0.000148	0.000218	CcSEcCtD
Topiramate—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000148	0.000217	CcSEcCtD
Topiramate—Insomnia—Doxorubicin—urinary bladder cancer	0.000147	0.000216	CcSEcCtD
Topiramate—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000146	0.000214	CcSEcCtD
Topiramate—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000145	0.000213	CcSEcCtD
Topiramate—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000144	0.000213	CcSEcCtD
Topiramate—Somnolence—Doxorubicin—urinary bladder cancer	0.000144	0.000212	CcSEcCtD
Topiramate—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000143	0.000211	CcSEcCtD
Topiramate—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000143	0.00021	CcSEcCtD
Topiramate—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000141	0.000207	CcSEcCtD
Topiramate—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	0.00014	0.000206	CcSEcCtD
Topiramate—Fatigue—Doxorubicin—urinary bladder cancer	0.00014	0.000206	CcSEcCtD
Topiramate—Urticaria—Epirubicin—urinary bladder cancer	0.000139	0.000205	CcSEcCtD
Topiramate—Constipation—Doxorubicin—urinary bladder cancer	0.000139	0.000204	CcSEcCtD
Topiramate—Pain—Doxorubicin—urinary bladder cancer	0.000139	0.000204	CcSEcCtD
Topiramate—Abdominal pain—Epirubicin—urinary bladder cancer	0.000139	0.000204	CcSEcCtD
Topiramate—Body temperature increased—Epirubicin—urinary bladder cancer	0.000139	0.000204	CcSEcCtD
Topiramate—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000138	0.000203	CcSEcCtD
Topiramate—Asthenia—Methotrexate—urinary bladder cancer	0.000134	0.000198	CcSEcCtD
Topiramate—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000134	0.000197	CcSEcCtD
Topiramate—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000133	0.000195	CcSEcCtD
Topiramate—Pruritus—Methotrexate—urinary bladder cancer	0.000133	0.000195	CcSEcCtD
Topiramate—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000129	0.00019	CcSEcCtD
Topiramate—Urticaria—Doxorubicin—urinary bladder cancer	0.000129	0.00019	CcSEcCtD
Topiramate—Body temperature increased—Doxorubicin—urinary bladder cancer	0.000128	0.000189	CcSEcCtD
Topiramate—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000128	0.000189	CcSEcCtD
Topiramate—Diarrhoea—Methotrexate—urinary bladder cancer	0.000128	0.000189	CcSEcCtD
Topiramate—Asthenia—Epirubicin—urinary bladder cancer	0.000126	0.000185	CcSEcCtD
Topiramate—Pruritus—Epirubicin—urinary bladder cancer	0.000124	0.000182	CcSEcCtD
Topiramate—Dizziness—Methotrexate—urinary bladder cancer	0.000124	0.000182	CcSEcCtD
Topiramate—Diarrhoea—Epirubicin—urinary bladder cancer	0.00012	0.000176	CcSEcCtD
Topiramate—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.00012	0.000176	CcSEcCtD
Topiramate—Vomiting—Methotrexate—urinary bladder cancer	0.000119	0.000175	CcSEcCtD
Topiramate—Rash—Methotrexate—urinary bladder cancer	0.000118	0.000174	CcSEcCtD
Topiramate—Dermatitis—Methotrexate—urinary bladder cancer	0.000118	0.000174	CcSEcCtD
Topiramate—Headache—Methotrexate—urinary bladder cancer	0.000117	0.000173	CcSEcCtD
Topiramate—Asthenia—Doxorubicin—urinary bladder cancer	0.000116	0.000171	CcSEcCtD
Topiramate—Dizziness—Epirubicin—urinary bladder cancer	0.000116	0.000171	CcSEcCtD
Topiramate—Pruritus—Doxorubicin—urinary bladder cancer	0.000115	0.000169	CcSEcCtD
Topiramate—Vomiting—Epirubicin—urinary bladder cancer	0.000111	0.000164	CcSEcCtD
Topiramate—Nausea—Methotrexate—urinary bladder cancer	0.000111	0.000164	CcSEcCtD
Topiramate—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000111	0.000163	CcSEcCtD
Topiramate—Rash—Epirubicin—urinary bladder cancer	0.000111	0.000163	CcSEcCtD
Topiramate—Dermatitis—Epirubicin—urinary bladder cancer	0.00011	0.000162	CcSEcCtD
Topiramate—Headache—Epirubicin—urinary bladder cancer	0.00011	0.000162	CcSEcCtD
Topiramate—Dizziness—Doxorubicin—urinary bladder cancer	0.000107	0.000158	CcSEcCtD
Topiramate—Nausea—Epirubicin—urinary bladder cancer	0.000104	0.000153	CcSEcCtD
Topiramate—Vomiting—Doxorubicin—urinary bladder cancer	0.000103	0.000152	CcSEcCtD
Topiramate—GRIA2—BDNF signaling pathway—HRAS—urinary bladder cancer	0.000103	0.000965	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	0.000103	0.000963	CbGpPWpGaD
Topiramate—CA6—Metabolism—GSTP1—urinary bladder cancer	0.000103	0.00096	CbGpPWpGaD
Topiramate—CA5A—Metabolism—GSTP1—urinary bladder cancer	0.000103	0.00096	CbGpPWpGaD
Topiramate—Rash—Doxorubicin—urinary bladder cancer	0.000102	0.00015	CcSEcCtD
Topiramate—CA9—Cellular responses to stress—EP300—urinary bladder cancer	0.000102	0.000957	CbGpPWpGaD
Topiramate—Dermatitis—Doxorubicin—urinary bladder cancer	0.000102	0.00015	CcSEcCtD
Topiramate—CA4—Metabolism—GSTT1—urinary bladder cancer	0.000102	0.000956	CbGpPWpGaD
Topiramate—Headache—Doxorubicin—urinary bladder cancer	0.000102	0.000149	CcSEcCtD
Topiramate—CA2—Metabolism—ENO2—urinary bladder cancer	0.000101	0.000945	CbGpPWpGaD
Topiramate—CA2—Metabolism—HPGDS—urinary bladder cancer	0.000101	0.000945	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.0001	0.000941	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—SRC—urinary bladder cancer	9.92e-05	0.000929	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	9.89e-05	0.000926	CbGpPWpGaD
Topiramate—CA2—Metabolism—GSTT1—urinary bladder cancer	9.78e-05	0.000916	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—RHOA—urinary bladder cancer	9.67e-05	0.000906	CbGpPWpGaD
Topiramate—CA1—Metabolism—ENO2—urinary bladder cancer	9.67e-05	0.000906	CbGpPWpGaD
Topiramate—CA1—Metabolism—HPGDS—urinary bladder cancer	9.67e-05	0.000906	CbGpPWpGaD
Topiramate—Nausea—Doxorubicin—urinary bladder cancer	9.64e-05	0.000142	CcSEcCtD
Topiramate—CA7—Metabolism—GSTP1—urinary bladder cancer	9.58e-05	0.000897	CbGpPWpGaD
Topiramate—CA5B—Metabolism—GSTP1—urinary bladder cancer	9.58e-05	0.000897	CbGpPWpGaD
Topiramate—CA6—Metabolism—TYMS—urinary bladder cancer	9.54e-05	0.000893	CbGpPWpGaD
Topiramate—CA5A—Metabolism—TYMS—urinary bladder cancer	9.54e-05	0.000893	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—RHOA—urinary bladder cancer	9.53e-05	0.000892	CbGpPWpGaD
Topiramate—CA5A—Metabolism—NCOR1—urinary bladder cancer	9.43e-05	0.000883	CbGpPWpGaD
Topiramate—CA6—Metabolism—NCOR1—urinary bladder cancer	9.43e-05	0.000883	CbGpPWpGaD
Topiramate—CA6—Metabolism—GSTM1—urinary bladder cancer	9.43e-05	0.000883	CbGpPWpGaD
Topiramate—CA5A—Metabolism—GSTM1—urinary bladder cancer	9.43e-05	0.000883	CbGpPWpGaD
Topiramate—CA1—Metabolism—GSTT1—urinary bladder cancer	9.38e-05	0.000878	CbGpPWpGaD
Topiramate—CYP2C19—Biological oxidations—GSTP1—urinary bladder cancer	9.36e-05	0.000876	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—GSTP1—urinary bladder cancer	9.23e-05	0.000864	CbGpPWpGaD
Topiramate—CA9—Metabolism—RRM2—urinary bladder cancer	9.18e-05	0.00086	CbGpPWpGaD
Topiramate—CA5A—Metabolism—GPX1—urinary bladder cancer	9.03e-05	0.000845	CbGpPWpGaD
Topiramate—CA6—Metabolism—GPX1—urinary bladder cancer	9.03e-05	0.000845	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	8.99e-05	0.000842	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—ERBB2—urinary bladder cancer	8.96e-05	0.000839	CbGpPWpGaD
Topiramate—CA7—Metabolism—TYMS—urinary bladder cancer	8.9e-05	0.000833	CbGpPWpGaD
Topiramate—CA5B—Metabolism—TYMS—urinary bladder cancer	8.9e-05	0.000833	CbGpPWpGaD
Topiramate—CA12—Metabolism—GSTP1—urinary bladder cancer	8.87e-05	0.000831	CbGpPWpGaD
Topiramate—CA6—Metabolism—ERCC2—urinary bladder cancer	8.86e-05	0.00083	CbGpPWpGaD
Topiramate—CA5A—Metabolism—ERCC2—urinary bladder cancer	8.86e-05	0.00083	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—ERBB2—urinary bladder cancer	8.82e-05	0.000826	CbGpPWpGaD
Topiramate—CA5B—Metabolism—GSTM1—urinary bladder cancer	8.8e-05	0.000824	CbGpPWpGaD
Topiramate—CA7—Metabolism—GSTM1—urinary bladder cancer	8.8e-05	0.000824	CbGpPWpGaD
Topiramate—CA7—Metabolism—NCOR1—urinary bladder cancer	8.8e-05	0.000824	CbGpPWpGaD
Topiramate—CA5B—Metabolism—NCOR1—urinary bladder cancer	8.8e-05	0.000824	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—EGFR—urinary bladder cancer	8.7e-05	0.000814	CbGpPWpGaD
Topiramate—GRIA1—Neuronal System—HRAS—urinary bladder cancer	8.68e-05	0.000813	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—CDK4—urinary bladder cancer	8.61e-05	0.000807	CbGpPWpGaD
Topiramate—CYP2C19—Biological oxidations—GSTM1—urinary bladder cancer	8.6e-05	0.000805	CbGpPWpGaD
Topiramate—CA9—Metabolism—ENO2—urinary bladder cancer	8.5e-05	0.000796	CbGpPWpGaD
Topiramate—CA9—Metabolism—HPGDS—urinary bladder cancer	8.5e-05	0.000796	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	8.48e-05	0.000794	CbGpPWpGaD
Topiramate—CA4—Metabolism—NQO1—urinary bladder cancer	8.48e-05	0.000794	CbGpPWpGaD
Topiramate—CYP2C19—Metapathway biotransformation—GSTM1—urinary bladder cancer	8.48e-05	0.000794	CbGpPWpGaD
Topiramate—CA7—Metabolism—GPX1—urinary bladder cancer	8.43e-05	0.000789	CbGpPWpGaD
Topiramate—CA5B—Metabolism—GPX1—urinary bladder cancer	8.43e-05	0.000789	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	8.37e-05	0.000784	CbGpPWpGaD
Topiramate—CA6—Metabolism—MTHFR—urinary bladder cancer	8.33e-05	0.00078	CbGpPWpGaD
Topiramate—CA5A—Metabolism—MTHFR—urinary bladder cancer	8.33e-05	0.00078	CbGpPWpGaD
Topiramate—CA5B—Metabolism—ERCC2—urinary bladder cancer	8.27e-05	0.000775	CbGpPWpGaD
Topiramate—CA7—Metabolism—ERCC2—urinary bladder cancer	8.27e-05	0.000775	CbGpPWpGaD
Topiramate—CA12—Metabolism—TYMS—urinary bladder cancer	8.25e-05	0.000772	CbGpPWpGaD
Topiramate—CA9—Metabolism—GSTT1—urinary bladder cancer	8.25e-05	0.000772	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—KRAS—urinary bladder cancer	8.22e-05	0.000769	CbGpPWpGaD
Topiramate—CA12—Metabolism—NCOR1—urinary bladder cancer	8.15e-05	0.000763	CbGpPWpGaD
Topiramate—CA12—Metabolism—GSTM1—urinary bladder cancer	8.15e-05	0.000763	CbGpPWpGaD
Topiramate—CA2—Metabolism—NQO1—urinary bladder cancer	8.13e-05	0.000761	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	8.12e-05	0.00076	CbGpPWpGaD
Topiramate—GRIK2—Neuronal System—HRAS—urinary bladder cancer	7.94e-05	0.000744	CbGpPWpGaD
Topiramate—GRIA2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	7.93e-05	0.000742	CbGpPWpGaD
Topiramate—GABRB2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	7.92e-05	0.000742	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—PPARG—urinary bladder cancer	7.83e-05	0.000733	CbGpPWpGaD
Topiramate—CA12—Metabolism—GPX1—urinary bladder cancer	7.81e-05	0.000731	CbGpPWpGaD
Topiramate—CA1—Metabolism—NQO1—urinary bladder cancer	7.8e-05	0.00073	CbGpPWpGaD
Topiramate—CA5B—Metabolism—MTHFR—urinary bladder cancer	7.78e-05	0.000728	CbGpPWpGaD
Topiramate—CA7—Metabolism—MTHFR—urinary bladder cancer	7.78e-05	0.000728	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—MMP9—urinary bladder cancer	7.68e-05	0.000719	CbGpPWpGaD
Topiramate—CA12—Metabolism—ERCC2—urinary bladder cancer	7.66e-05	0.000718	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—MMP9—urinary bladder cancer	7.57e-05	0.000709	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—CREBBP—urinary bladder cancer	7.52e-05	0.000704	CbGpPWpGaD
Topiramate—CA9—Cellular responses to stress—TP53—urinary bladder cancer	7.32e-05	0.000685	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—EP300—urinary bladder cancer	7.28e-05	0.000682	CbGpPWpGaD
Topiramate—GABRG2—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	7.24e-05	0.000678	CbGpPWpGaD
Topiramate—CA12—Metabolism—MTHFR—urinary bladder cancer	7.2e-05	0.000675	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—SRC—urinary bladder cancer	7.08e-05	0.000663	CbGpPWpGaD
Topiramate—CA4—Metabolism—GSTP1—urinary bladder cancer	7.07e-05	0.000662	CbGpPWpGaD
Topiramate—SCN1A—Axon guidance—HRAS—urinary bladder cancer	6.98e-05	0.000654	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—SRC—urinary bladder cancer	6.98e-05	0.000653	CbGpPWpGaD
Topiramate—GABRA1—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	6.89e-05	0.000645	CbGpPWpGaD
Topiramate—CA9—Metabolism—NQO1—urinary bladder cancer	6.85e-05	0.000642	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—RHOA—urinary bladder cancer	6.8e-05	0.000637	CbGpPWpGaD
Topiramate—CA2—Metabolism—GSTP1—urinary bladder cancer	6.78e-05	0.000635	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PPARG—urinary bladder cancer	6.75e-05	0.000632	CbGpPWpGaD
Topiramate—CA6—Metabolism—PPARG—urinary bladder cancer	6.75e-05	0.000632	CbGpPWpGaD
Topiramate—CA4—Metabolism—TYMS—urinary bladder cancer	6.58e-05	0.000616	CbGpPWpGaD
Topiramate—CA1—Metabolism—GSTP1—urinary bladder cancer	6.5e-05	0.000609	CbGpPWpGaD
Topiramate—CA4—Metabolism—GSTM1—urinary bladder cancer	6.5e-05	0.000609	CbGpPWpGaD
Topiramate—CA4—Metabolism—NCOR1—urinary bladder cancer	6.5e-05	0.000609	CbGpPWpGaD
Topiramate—CA5A—Metabolism—CREBBP—urinary bladder cancer	6.49e-05	0.000608	CbGpPWpGaD
Topiramate—CA6—Metabolism—CREBBP—urinary bladder cancer	6.49e-05	0.000608	CbGpPWpGaD
Topiramate—GABRA1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—urinary bladder cancer	6.33e-05	0.000593	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PPARG—urinary bladder cancer	6.31e-05	0.00059	CbGpPWpGaD
Topiramate—CA7—Metabolism—PPARG—urinary bladder cancer	6.31e-05	0.00059	CbGpPWpGaD
Topiramate—CA2—Metabolism—TYMS—urinary bladder cancer	6.31e-05	0.00059	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—ERBB2—urinary bladder cancer	6.3e-05	0.00059	CbGpPWpGaD
Topiramate—CA2—Metabolism—NCOR1—urinary bladder cancer	6.23e-05	0.000584	CbGpPWpGaD
Topiramate—CA2—Metabolism—GSTM1—urinary bladder cancer	6.23e-05	0.000584	CbGpPWpGaD
Topiramate—CA4—Metabolism—GPX1—urinary bladder cancer	6.23e-05	0.000583	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—EGFR—urinary bladder cancer	6.21e-05	0.000581	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—EGFR—urinary bladder cancer	6.12e-05	0.000573	CbGpPWpGaD
Topiramate—CA4—Metabolism—ERCC2—urinary bladder cancer	6.11e-05	0.000572	CbGpPWpGaD
Topiramate—GRIA2—Neuronal System—HRAS—urinary bladder cancer	6.07e-05	0.000569	CbGpPWpGaD
Topiramate—CA7—Metabolism—CREBBP—urinary bladder cancer	6.06e-05	0.000567	CbGpPWpGaD
Topiramate—CA5B—Metabolism—CREBBP—urinary bladder cancer	6.06e-05	0.000567	CbGpPWpGaD
Topiramate—CA1—Metabolism—TYMS—urinary bladder cancer	6.04e-05	0.000566	CbGpPWpGaD
Topiramate—CA1—Metabolism—GSTM1—urinary bladder cancer	5.98e-05	0.000559	CbGpPWpGaD
Topiramate—CA1—Metabolism—NCOR1—urinary bladder cancer	5.98e-05	0.000559	CbGpPWpGaD
Topiramate—CA2—Metabolism—GPX1—urinary bladder cancer	5.97e-05	0.000559	CbGpPWpGaD
Topiramate—GABRB2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.95e-05	0.000557	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—TNF—urinary bladder cancer	5.91e-05	0.000554	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—KRAS—urinary bladder cancer	5.86e-05	0.000549	CbGpPWpGaD
Topiramate—CA2—Metabolism—ERCC2—urinary bladder cancer	5.86e-05	0.000549	CbGpPWpGaD
Topiramate—CA12—Metabolism—PPARG—urinary bladder cancer	5.84e-05	0.000547	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—KRAS—urinary bladder cancer	5.78e-05	0.000541	CbGpPWpGaD
Topiramate—CA4—Metabolism—MTHFR—urinary bladder cancer	5.75e-05	0.000538	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GSTZ1—urinary bladder cancer	5.73e-05	0.000537	CbGpPWpGaD
Topiramate—CA1—Metabolism—GPX1—urinary bladder cancer	5.72e-05	0.000536	CbGpPWpGaD
Topiramate—CA9—Metabolism—GSTP1—urinary bladder cancer	5.72e-05	0.000535	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	5.63e-05	0.000527	CbGpPWpGaD
Topiramate—CA1—Metabolism—ERCC2—urinary bladder cancer	5.62e-05	0.000526	CbGpPWpGaD
Topiramate—CA12—Metabolism—CREBBP—urinary bladder cancer	5.61e-05	0.000525	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.55e-05	0.00052	CbGpPWpGaD
Topiramate—CA2—Metabolism—MTHFR—urinary bladder cancer	5.51e-05	0.000516	CbGpPWpGaD
Topiramate—GABRG2—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	5.45e-05	0.00051	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GSTO2—urinary bladder cancer	5.43e-05	0.000509	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—NAT1—urinary bladder cancer	5.43e-05	0.000509	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—MMP9—urinary bladder cancer	5.4e-05	0.000506	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	5.34e-05	0.0005	CbGpPWpGaD
Topiramate—CA9—Metabolism—TYMS—urinary bladder cancer	5.31e-05	0.000498	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PTGS2—urinary bladder cancer	5.31e-05	0.000498	CbGpPWpGaD
Topiramate—CA6—Metabolism—PTGS2—urinary bladder cancer	5.31e-05	0.000498	CbGpPWpGaD
Topiramate—CA1—Metabolism—MTHFR—urinary bladder cancer	5.28e-05	0.000494	CbGpPWpGaD
Topiramate—GABRB2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	5.26e-05	0.000493	CbGpPWpGaD
Topiramate—CA9—Metabolism—GSTM1—urinary bladder cancer	5.25e-05	0.000492	CbGpPWpGaD
Topiramate—CA9—Metabolism—NCOR1—urinary bladder cancer	5.25e-05	0.000492	CbGpPWpGaD
Topiramate—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	5.17e-05	0.000484	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—EP300—urinary bladder cancer	5.12e-05	0.000479	CbGpPWpGaD
Topiramate—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	5.1e-05	0.000478	CbGpPWpGaD
Topiramate—CA9—Metabolism—GPX1—urinary bladder cancer	5.03e-05	0.000471	CbGpPWpGaD
Topiramate—SCN1A—Developmental Biology—HRAS—urinary bladder cancer	4.98e-05	0.000467	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—SRC—urinary bladder cancer	4.98e-05	0.000466	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—UGT2B7—urinary bladder cancer	4.97e-05	0.000465	CbGpPWpGaD
Topiramate—CA7—Metabolism—PTGS2—urinary bladder cancer	4.96e-05	0.000464	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PTGS2—urinary bladder cancer	4.96e-05	0.000464	CbGpPWpGaD
Topiramate—CA9—Metabolism—ERCC2—urinary bladder cancer	4.94e-05	0.000462	CbGpPWpGaD
Topiramate—SCN5A—Axon guidance—HRAS—urinary bladder cancer	4.91e-05	0.00046	CbGpPWpGaD
Topiramate—GABRG2—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.81e-05	0.000451	CbGpPWpGaD
Topiramate—GABRA1—Transmission across Chemical Synapses—HRAS—urinary bladder cancer	4.76e-05	0.000446	CbGpPWpGaD
Topiramate—CA4—Metabolism—PPARG—urinary bladder cancer	4.66e-05	0.000436	CbGpPWpGaD
Topiramate—CA9—Metabolism—MTHFR—urinary bladder cancer	4.64e-05	0.000435	CbGpPWpGaD
Topiramate—CA6—Metabolism—PTEN—urinary bladder cancer	4.63e-05	0.000434	CbGpPWpGaD
Topiramate—CA5A—Metabolism—PTEN—urinary bladder cancer	4.63e-05	0.000434	CbGpPWpGaD
Topiramate—CA12—Metabolism—PTGS2—urinary bladder cancer	4.6e-05	0.00043	CbGpPWpGaD
Topiramate—GABRB2—Neuronal System—HRAS—urinary bladder cancer	4.56e-05	0.000427	CbGpPWpGaD
Topiramate—CA4—Metabolism—CREBBP—urinary bladder cancer	4.48e-05	0.000419	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CYP4B1—urinary bladder cancer	4.47e-05	0.000419	CbGpPWpGaD
Topiramate—CA2—Metabolism—PPARG—urinary bladder cancer	4.47e-05	0.000418	CbGpPWpGaD
Topiramate—CA5A—Metabolism—EP300—urinary bladder cancer	4.42e-05	0.000414	CbGpPWpGaD
Topiramate—CA6—Metabolism—EP300—urinary bladder cancer	4.42e-05	0.000414	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—EGFR—urinary bladder cancer	4.36e-05	0.000409	CbGpPWpGaD
Topiramate—CA5B—Metabolism—PTEN—urinary bladder cancer	4.33e-05	0.000405	CbGpPWpGaD
Topiramate—CA7—Metabolism—PTEN—urinary bladder cancer	4.33e-05	0.000405	CbGpPWpGaD
Topiramate—CA2—Metabolism—CREBBP—urinary bladder cancer	4.29e-05	0.000402	CbGpPWpGaD
Topiramate—CA1—Metabolism—PPARG—urinary bladder cancer	4.28e-05	0.000401	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—SLC19A1—urinary bladder cancer	4.23e-05	0.000396	CbGpPWpGaD
Topiramate—GABRA1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	4.21e-05	0.000394	CbGpPWpGaD
Topiramate—GABRG2—Neuronal System—HRAS—urinary bladder cancer	4.17e-05	0.000391	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—TNF—urinary bladder cancer	4.16e-05	0.000389	CbGpPWpGaD
Topiramate—CA5B—Metabolism—EP300—urinary bladder cancer	4.13e-05	0.000386	CbGpPWpGaD
Topiramate—CA7—Metabolism—EP300—urinary bladder cancer	4.13e-05	0.000386	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—KRAS—urinary bladder cancer	4.12e-05	0.000386	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PRSS3—urinary bladder cancer	4.12e-05	0.000386	CbGpPWpGaD
Topiramate—CA1—Metabolism—CREBBP—urinary bladder cancer	4.11e-05	0.000385	CbGpPWpGaD
Topiramate—CA12—Metabolism—PTEN—urinary bladder cancer	4.01e-05	0.000375	CbGpPWpGaD
Topiramate—CA12—Metabolism—EP300—urinary bladder cancer	3.82e-05	0.000358	CbGpPWpGaD
Topiramate—CA9—Metabolism—PPARG—urinary bladder cancer	3.76e-05	0.000352	CbGpPWpGaD
Topiramate—CA4—Metabolism—PTGS2—urinary bladder cancer	3.66e-05	0.000343	CbGpPWpGaD
Topiramate—GABRA1—Neuronal System—HRAS—urinary bladder cancer	3.65e-05	0.000341	CbGpPWpGaD
Topiramate—CA9—Metabolism—CREBBP—urinary bladder cancer	3.62e-05	0.000339	CbGpPWpGaD
Topiramate—CA2—Metabolism—PTGS2—urinary bladder cancer	3.51e-05	0.000329	CbGpPWpGaD
Topiramate—SCN5A—Developmental Biology—HRAS—urinary bladder cancer	3.5e-05	0.000328	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	3.45e-05	0.000323	CbGpPWpGaD
Topiramate—CA1—Metabolism—PTGS2—urinary bladder cancer	3.37e-05	0.000315	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	3.3e-05	0.000309	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—TYMP—urinary bladder cancer	3.29e-05	0.000308	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	3.27e-05	0.000306	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—NAT1—urinary bladder cancer	3.27e-05	0.000306	CbGpPWpGaD
Topiramate—CA4—Metabolism—PTEN—urinary bladder cancer	3.2e-05	0.000299	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	3.16e-05	0.000296	CbGpPWpGaD
Topiramate—CA2—Metabolism—PTEN—urinary bladder cancer	3.06e-05	0.000287	CbGpPWpGaD
Topiramate—CA4—Metabolism—EP300—urinary bladder cancer	3.05e-05	0.000285	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	2.99e-05	0.00028	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—NAT2—urinary bladder cancer	2.98e-05	0.000279	CbGpPWpGaD
Topiramate—CA9—Metabolism—PTGS2—urinary bladder cancer	2.96e-05	0.000277	CbGpPWpGaD
Topiramate—CA1—Metabolism—PTEN—urinary bladder cancer	2.94e-05	0.000275	CbGpPWpGaD
Topiramate—CA2—Metabolism—EP300—urinary bladder cancer	2.92e-05	0.000274	CbGpPWpGaD
Topiramate—CA1—Metabolism—EP300—urinary bladder cancer	2.8e-05	0.000262	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	2.69e-05	0.000252	CbGpPWpGaD
Topiramate—CA9—Metabolism—PTEN—urinary bladder cancer	2.58e-05	0.000242	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—RRM2—urinary bladder cancer	2.57e-05	0.000241	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	2.54e-05	0.000238	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	2.48e-05	0.000232	CbGpPWpGaD
Topiramate—CA9—Metabolism—EP300—urinary bladder cancer	2.46e-05	0.000231	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—ENO2—urinary bladder cancer	2.38e-05	0.000223	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—HPGDS—urinary bladder cancer	2.38e-05	0.000223	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	2.37e-05	0.000222	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GSTT1—urinary bladder cancer	2.31e-05	0.000216	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	2.27e-05	0.000213	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—TYMP—urinary bladder cancer	1.98e-05	0.000185	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—NQO1—urinary bladder cancer	1.92e-05	0.00018	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	1.86e-05	0.000174	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—NAT2—urinary bladder cancer	1.79e-05	0.000168	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	1.62e-05	0.000152	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GSTP1—urinary bladder cancer	1.6e-05	0.00015	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	1.55e-05	0.000145	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—RRM2—urinary bladder cancer	1.55e-05	0.000145	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—TYMS—urinary bladder cancer	1.49e-05	0.000139	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—NCOR1—urinary bladder cancer	1.47e-05	0.000138	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GSTM1—urinary bladder cancer	1.47e-05	0.000138	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—ENO2—urinary bladder cancer	1.43e-05	0.000134	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	1.43e-05	0.000134	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—GPX1—urinary bladder cancer	1.41e-05	0.000132	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	1.39e-05	0.00013	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—ERCC2—urinary bladder cancer	1.38e-05	0.000129	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—MTHFR—urinary bladder cancer	1.3e-05	0.000122	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—NQO1—urinary bladder cancer	1.15e-05	0.000108	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PPARG—urinary bladder cancer	1.05e-05	9.87e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—CREBBP—urinary bladder cancer	1.01e-05	9.48e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	9.62e-06	9.01e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—TYMS—urinary bladder cancer	8.95e-06	8.38e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	8.84e-06	8.28e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	8.84e-06	8.28e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—GPX1—urinary bladder cancer	8.47e-06	7.93e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	8.31e-06	7.78e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PTGS2—urinary bladder cancer	8.29e-06	7.76e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	7.82e-06	7.32e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—PTEN—urinary bladder cancer	7.23e-06	6.77e-05	CbGpPWpGaD
Topiramate—CYP2C19—Metabolism—EP300—urinary bladder cancer	6.9e-06	6.46e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PPARG—urinary bladder cancer	6.34e-06	5.93e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	6.09e-06	5.7e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	4.99e-06	4.67e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—PTEN—urinary bladder cancer	4.35e-06	4.07e-05	CbGpPWpGaD
Topiramate—CYP3A4—Metabolism—EP300—urinary bladder cancer	4.15e-06	3.88e-05	CbGpPWpGaD
